{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000093","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.379389+00:00","generated_at":"2026-05-17T06:59:46.286591+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Intensity Therapeutics pauses INVINCIBLE-4 enrollment after skin irritation; first Cohort A patient achieves pCR","bullets":["First patient in Cohort A achieved pathological complete response after two INT230-6 doses plus immunochemotherapy.","Cohort A patients received INT230-6 eight days apart followed by standard-of-care immunochemotherapy.","Safety profile described as favorable, but localized skin irritation near tumor site observed in some patients.","Enrollment paused to evaluate data and implement adjustments before reopening."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000093","json":"https://secwatch.observer/filing/0001567264-25-000093.json","markdown":"https://secwatch.observer/filing/0001567264-25-000093.md","text":"https://secwatch.observer/filing/0001567264-25-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000093/0001567264-25-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000093/intensity-20250910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:59:46.286591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}